Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

4.98
+0.18003.75%
Volume:72.29K
Turnover:360.55K
Market Cap:291.74M
PE:-4.22
High:5.10
Open:4.88
Low:4.88
Close:4.80
52wk High:6.95
52wk Low:2.94
Shares:58.58M
Float Shares:28.87M
Volume Ratio:0.53
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1800
EPS(LYR):-1.1800
ROE:-470.38%
ROA:-21.29%
PB:-2.69
PE(LYR):-4.22

Loading ...

Foghorn Therapeutics Q3 Collaboration Revenue USD 8.153 Million

THOMSON REUTERS
·
Nov 05, 2025

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

GlobeNewswire
·
Nov 05, 2025

Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating

TIPRANKS
·
Nov 04, 2025

Foghorn Therapeutics to Participate in Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 03, 2025

Foghorn Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
Oct 31, 2025

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Bicycle Therapeutics (BCYC) and Foghorn Therapeutics (FHTX)

TIPRANKS
·
Oct 31, 2025

Foghorn Therapeutics Inc - Selective Cbp Degrader Ind-Ready in 2026

THOMSON REUTERS
·
Oct 30, 2025

Foghorn Therapeutics Inc - Selective Arid1b Degrader Relevant in 5% of Solid Tumors

THOMSON REUTERS
·
Oct 30, 2025

Foghorn Therapeutics Announces Updates for Selective Arid1b, Selective Cbp and Selective Ep300 Degrader Programs

THOMSON REUTERS
·
Oct 30, 2025

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

GlobeNewswire
·
Oct 30, 2025

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader Program Targeting Cancer at TPD Summit

Reuters
·
Oct 16, 2025

Foghorn Therapeutics Announces Significant Progress for Selective Arid1b Degrader at the 8TH Annual Tpd and Induced Proximity Summit

THOMSON REUTERS
·
Oct 16, 2025

Foghorn Therapeutics transferred with Buy rating at B. Riley

TIPRANKS
·
Sep 17, 2025